EP4259138A4 - Verfahren zur behandlung von herzerkrankungen mit modifizierten formen von trimetazidin - Google Patents

Verfahren zur behandlung von herzerkrankungen mit modifizierten formen von trimetazidin Download PDF

Info

Publication number
EP4259138A4
EP4259138A4 EP21904143.1A EP21904143A EP4259138A4 EP 4259138 A4 EP4259138 A4 EP 4259138A4 EP 21904143 A EP21904143 A EP 21904143A EP 4259138 A4 EP4259138 A4 EP 4259138A4
Authority
EP
European Patent Office
Prior art keywords
trimetazidine
methods
heart disease
modified forms
treating heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21904143.1A
Other languages
English (en)
French (fr)
Other versions
EP4259138A1 (de
Inventor
Jaikrishna Patel
Paul Chamberlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of EP4259138A1 publication Critical patent/EP4259138A1/de
Publication of EP4259138A4 publication Critical patent/EP4259138A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP21904143.1A 2020-12-10 2021-12-02 Verfahren zur behandlung von herzerkrankungen mit modifizierten formen von trimetazidin Pending EP4259138A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063123715P 2020-12-10 2020-12-10
US202063123728P 2020-12-10 2020-12-10
US202063123711P 2020-12-10 2020-12-10
US202063123721P 2020-12-10 2020-12-10
PCT/US2021/061583 WO2022125370A1 (en) 2020-12-10 2021-12-02 Methods of treating heart conditions using modified forms of trimetazidine

Publications (2)

Publication Number Publication Date
EP4259138A1 EP4259138A1 (de) 2023-10-18
EP4259138A4 true EP4259138A4 (de) 2024-11-06

Family

ID=82932763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21904143.1A Pending EP4259138A4 (de) 2020-12-10 2021-12-02 Verfahren zur behandlung von herzerkrankungen mit modifizierten formen von trimetazidin

Country Status (2)

Country Link
EP (1) EP4259138A4 (de)
WO (1) WO2022125370A1 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500365A (ja) * 2014-12-22 2018-01-11 カーディオラ ピーティーワイ リミテッド 治療方法
US11213514B2 (en) * 2016-02-26 2022-01-04 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
EP4497474A3 (de) * 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Verfahren zur behandlung von rheumatischen erkrankungen unter verwendung von trimetazidinbasierten verbindungen
US20220249463A1 (en) * 2019-05-31 2022-08-11 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation
WO2020247213A1 (en) * 2019-06-03 2020-12-10 Imbria Pharmaceuticals, Inc. Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERLINER DOMINIK ET AL: "The Treatment of Heart Failure with Reduced Ejection Fraction", 22 May 2020 (2020-05-22), XP093206987, ISSN: 1866-0452, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643567/pdf/Dtsch_Arztebl_Int-117_0376.pdf> DOI: 10.3238/arztebl.2020.0376 *
KLONER ROBERT A. ET AL: "Stunned and Hibernating Myocardium: Where Are We Nearly 4 Decades Later?", vol. 9, no. 3, 4 February 2020 (2020-02-04), XP093207112, ISSN: 2047-9980, Retrieved from the Internet <URL:https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.015502> DOI: 10.1161/JAHA.119.015502 *
MARON MARTIN S ET AL: "Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 67, no. 12, 21 March 2016 (2016-03-21), pages 1399 - 1409, XP029469187, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2016.01.023 *
See also references of WO2022125370A1 *

Also Published As

Publication number Publication date
EP4259138A1 (de) 2023-10-18
WO2022125370A8 (en) 2022-08-25
WO2022125370A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
EP3931564A4 (de) Verfahren zur behandlung von map3k8-positiven tumoren
EP4117659A4 (de) Verfahren zur behandlung von atemwegserkrankungen mit deupirifenidon
EP3994159A4 (de) Verfahren zur behandlung von mit ran-protein assoziierten neurologischen krankheiten
EP4301410A4 (de) Verfahren zur behandlung von schilddrüsenaugenkrankheit
EP3941921A4 (de) Therapeutische verfahren zur behandlung von hepatitis b
EP4248212A4 (de) Verfahren zur behandlung von krankheiten und störungen
EP3958869A4 (de) Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen im zusammenhang mit biofilm
EP3990090A4 (de) Freisetzungskatheter und verfahren zur behandlung von krankheiten
EP3565540A4 (de) Verfahren zur behandlung von herz-kreislauf-erkrankungen
EP4460525A4 (de) Zusammensetzungen und verfahren zur behandlung von schilddrüsenaugenkrankheit
EP4229828A4 (de) Verfahren zur behandlung von fibrose
EP4262814A4 (de) Verfahren zur behandlung von störungen im zusammenhang mit rizinus
EP3893883A4 (de) Verfahren zur behandlung von depression
EP3829651A4 (de) Verfahren zur identifizierung von patienten, die wahrscheinlich von der behandlung mit einem telomerasehemmer profitieren
EP4429701A4 (de) Verfahren zur behandlung oder hemmung von herz-kreislauf-erkrankungen
EP3746067A4 (de) Zusammensetzungen und verfahren zur behandlung von lungenödem oder lungenentzündung
EP4117662A4 (de) Verfahren zur behandlung von neutropenie
EP4419101A4 (de) Verfahren zur behandlung von zns-erkrankungen
EP3914589A4 (de) Verfahren zur behandlung von krankheiten mit magl-hemmern
EP4322985A4 (de) Verfahren zur behandlung von retinalen gefässerkrankungen
EP4225371A4 (de) Verfahren zur behandlung von ox40-verwandten krankheiten
EP4146215A4 (de) Dosierverfahren zur behandlung von kardiovaskulären erkrankungen
EP4025234A4 (de) Verfahren und verwendung von pnpp-19 zur vorbeugung und behandlung von augenkrankheiten
EP3999053A4 (de) Verfahren zur behandlung von neoplastischen erkrankungen mit einem cdc42-spezifischen inhibitor
EP4395752A4 (de) Verfahren zur behandlung von cb1-, trpa1- und trpv1-abhängigen erkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230606

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231221

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20241008

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 295/088 20060101ALI20241001BHEP

Ipc: A61K 31/497 20060101ALI20241001BHEP

Ipc: C07D 213/80 20060101ALI20241001BHEP

Ipc: C07D 401/12 20060101ALI20241001BHEP

Ipc: C07D 241/04 20060101ALI20241001BHEP

Ipc: C07D 241/02 20060101ALI20241001BHEP

Ipc: A61P 9/00 20060101ALI20241001BHEP

Ipc: A61K 31/496 20060101ALI20241001BHEP

Ipc: A61K 31/495 20060101ALI20241001BHEP

Ipc: A61K 31/455 20060101AFI20241001BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250926